

Funding Deals

(January 1st – January 31st, 2012)

Pharma/Biotech

1)	<p>Ossianix Inc., a privately held Philadelphia biopharmaceutical company received funding from H. Lundbeck, a Danish pharmaceutical company in the form of a convertible promissory note. The amount of the investment by Lundbeck was not disclosed. Ossianix, founded in 2011, is developing experimental treatments for nervous system disorders by using its proprietary single-domain antibody platform modeled on a structure found in sharks.</p>
	Philadelphia Business Journal, 1/3/12
2)	<p>Elevation Pharmaceuticals Inc. closed \$30 million in Series B financing led by new investor Novo Ventures. The company, which develops aerosol therapy for patients living with chronic obstructive pulmonary disease, was also backed in the round by previous investors including Canaan Partners, TPG Biotech, Care Capital, and Mesa Verde Venture Partners.</p>
	PeHUB, 1/4/12
3)	<p>ImmuneXcite Inc., a Cambridge biotech startup secured \$2.48 million in its first institutional funding round, according to a filing. A total of 36 undisclosed backers contributed to this first round. At a MTTC presentation, ImmuneXcite said it is developing a platform product that will elicit an immune response to cancer cells, based on the research of co-founder and chief scientific officer Ifat Rubin-Bejerano, a senior researcher at the Whitehead Institute at MIT. Rubin-Bejerano discovered a polysaccharide found on the cell walls of fungal cells, which triggers the body's immune response to such cells if there is a fungal infection. It is hypothesized that the polysaccharide will trigger a "very aggressive immune cell" response to this "fungi looking" target cells.</p>
	Mass High Tech, 1/4/12
4)	<p>GITR Inc., a stealth biotech startup lead by Gus Lawlor of Health Care Ventures LLC raised \$1.25 million in a first funding round. Only a single unnamed investor is listed in the filing. GITR has no website, but the company name indicates that the "novel immunomodulatory response" is based on the GITR (glucocorticoid-induced tumor necrosis factor receptor) found on immune system cells, and the company is developing therapies to enhance the immune system by enabling T cells to be more effective in attacking cancer cells. This receptor was also the target of therapies being developed by Cambridge biotech Tolerx Inc that auctioning off its assets not associated with a GlaxoSmithKline partnership in Oct 2011 and two rounds of layoffs.</p>
	Mass High Tech, 1/4/12
5)	<p>NeuroGenetic Pharmaceuticals Inc. (NGP), a San Diego-based developer of Alzheimer's disease therapeutics, has raised an undisclosed amount of financing from Abbott Biotech Ventures. NGP 555 is a small molecule modulator of the gamma-secretase complex. NGP 555 is a potent molecule, which crosses the blood-brain barrier and is effective in lowering</p>

	the brain biomarkers A β 42 and A β 40 while showing an increase in the A β 38 peptide with no effect on Notch processing.
	Fortune, 1/5/12
6)	Syndexa Pharmaceuticals Corp. , a Watertown, Mass.-based company raised an undisclosed amount of Series B1 financing from MP Healthcare Venture Management. Total capital raised in the B1 round was \$8.5 million. Syndexa is developing drugs to treat metabolic diseases.
	PeHUB, 1/5/12
7)	Tivorsan Pharmaceuticals Inc. a Rhode Island biotech startup won a \$1 million funding award from the Muscular Dystrophy Association (MDA) to support the company's development of a muscular dystrophy treatment candidate. Tivorsan's drug treatment, TVN-102, a recombinant humanized form of biglycan, a protein found naturally on muscle fiber membranes has been tested on mice with Duchenne muscular dystrophy, a genetic muscle-weakening disease that affects boys, and was found to aid muscle function while reducing muscle degeneration.
	Mass High Tech, 1/5/12
8)	3-V Biosciences Inc. , a Menlo Park-based company closed a preferred stock financing for a minimum of \$20 million. Existing investors Menlo Park-based Kleiner Perkins Caufield & Byers and New Enterprise Associates contributed equally to the financing. The company's novel program targets a host-factor for treating the Hepatitis C virus. 3-V plans to use the funds to advance its HCV program, for earlier-stage pipeline opportunities and screening.
	Silicon Valley / San Jose Business Journal, 1/6/12
9)	Supernus Pharmaceuticals Inc. , Rockville-based company who filed an IPO to raise \$100 million in a public stock offering in December 2010, has delayed the IPO but raised \$42 million in December in two separate transactions. Supernus sold its TCD Royalty Subsidiary to an undisclosed buyer for \$27 million, and raised another \$15 million in venture debt. The company will prepare for the commercial launch of its two epilepsy drugs and to continue development of treatments for central nervous system diseases. The epilepsy drugs are awaiting Food and Drug Administration approval.
	Washington Business Journal, 1/6/12
10)	Blend Therapeutics , a Watertown, Mass.-based developer of combination medicines, has raised and undisclosed amount Series A funding. Backers include Flagship Ventures, New Enterprise Associates, and NanoDimension. VentureWire reports that the round came in at \$2.8 million, with plans to raise a \$15 million Series B round later this year.
	Fortune, 1/9/12
11)	BerGenBio , a Bergen, Norway oncology biopharma start-up, has raised \$8.8 million in Series A financing from Norwegian venture investors Sarsia Seed AS and Investinor AS. The money will go toward taking its lead product into clinical trials. BerGenBio is focus on developing a first-in-class Axl kinase inhibitor drug, rapidly towards clinical trials.

	BGB324 recently attracted a great deal of attention at the annual American Society for Hematology conference in San Diego, where data presented showed the compound inhibited tumor development in preclinical Acute Myelogenous Leukemia (AML) models. PeHUB, 1/9/12
12)	Avaxia Biologics Inc. , a Lexington-based developer of oral antibody drugs for the gastrointestinal tract, has raised a total of \$3.44 million out of the \$4.46 million equity offering initiated late last year, according to a filing on Jan. 6, according to CEO and founder Barbara Fox told Mass High Tech in an email. “The full Series A will be used to fund the remaining preclinical work on AVX-470, our oral anti-TNF antibody, before initiating clinical testing in patients with Crohn’s disease. Mass High Tech, 1/9/12
13)	Telormedix , a Swiss biotech company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, has raised CHF 7.5 million (\$7.9m) in new VC funding from return backers Aravis Ventures and Proquest Investments. Fortune, 1/10/12
14)	Warp Drive Bio , a new biotech startup launched by Boston venture capital firm Third Rock Ventures secured \$125 million from Sanofi. Warp Drive Bio, whose launch was just announced in a news release, is developing natural-product drugs using a proprietary genomics technology. It was founded and incubated at Third Rock by genome scientists Gregory Verdine, George Church, and James Wells. Boston Business Journal, 1/10/12
15)	Avexxin , a company focusing on the development of novel small molecule therapeutics for patients suffering from chronic inflammatory conditions such as psoriasis, announced the second closing of an undisclosed series A funding round with existing shareholders. This will enable the company to take its lead compound against psoriasis through early clinical development. Norwegian seed capital fund Sarsia Seed is a backer of the company. PeHUB, 1/11/12
16)	Pulse Therapeutics Inc. a St. Louis, Missouri company raised \$3 million in new financing, according to a regulatory filing. Pulse Therapeutics is developing stroke treatment technology designed to destroy blood clots. Investors include St. Louis-based seed investor BioGenerator. PeHUB, 1/13/12
17)	Heat Biologics , a Chapel Hill, N.C.-based biotech company, raised \$2.8 million in new funding. The company is aiming to raise as much as \$4.1 million in the round, according to the filing. In May 2010, Heat Biologics announced an undisclosed amount of financing from Brightline Ventures. The company is focused on oncology and virology products. PeHUB, 1/13/12
18)	CrystalGenomics Inc. , a clinical stage biopharmaceutical company based in Korea secured \$2.6 million from The Korea Seoul Life Science Fund. The company raised a total

	of \$20 million across these round and previous bond issuances. The company will use the money for continued research and development.
	PeHUB, 1/13/12
19)	Koronis Pharma Inc. , a Seattle-based developer of antiviral therapeutics, raised \$1 million of a planned \$2 million round according to a regulatory filing. The company is backed by investors including Helix Ventures.
	PeHUB, 1/13/12
20)	Thrombolytic Science International LLC , a Cambridge, Mass.-based developer of drugs to treat strokes and heart attacks, raised \$7.5 million from a European family trust, according to VentureWire.
	Fortune, 1/13/12
21)	RaNA Therapeutics Inc. , a secretive Cambridge-based company developing technology licensed from Mass General Hospital (MGH), completed a \$20.7 million Series A round co-led by Atlas Venture, SR One, and Monsanto Co., with participation from Partners Innovation Fund. "Our platform is based on a new therapeutic approach to selectively up-regulate gene expression (a type of regulatory RNA called long non-coding RNA (lncRNA))," Dr. Arthur Krieg, RaNA's president and CEO, told Mass High Tech. The company already has conducted in vitro ("test tube") and in vivo ("inside the body") experiments that indicate the technology would have broad therapeutic uses.
	Mass High Tech, 1/18/12
22)	Vitae Pharmaceuticals secured a \$15 million round of debt financing from Oxford Finance, a specialty finance firm that provides senior debt to life sciences and healthcare services companies and Silicon Valley Bank. The funds will be used to support the progress of Vitae's drug pipeline, which includes treatments for chronic kidney disease, diabetes, Alzheimer's disease, and atherosclerosis.
	PeHUB, 1/19/12
23)	KeraNetics , a Winston-Salem, N.C.-based company hoping to raise \$7 million, secured \$4.7 million in a round of financing from 26 investors. The offering is a mix of equity, options, and warrants. The company is pursuing keratin-based regenerative medicine and trauma products, including one designed for healing damaged tissue that is targeted for use initially by the U.S. military.
	MedCityNews, 1/20/12
24)	X-Body Inc. , a Waltham biotech boosted its fundraising tranche to \$4.14 million, almost reaching the top end of \$4.17 million but now has a new end goal of \$7.17 million. In an SEC filing, X-Body – aka X-Body Biosciences – noted that it had just a single unidentified backer in this tranche, as opposed to the two investors noted in the November tranche. President and CEO Wagner said that the new and previous tranche was an inside funding round. X-Body is focused on technology to discover and develop human antibodies to treat certain types of cancer and other diseases.
	Mass High Tech, 1/23/12

25)	<p>Aphios Corp., a Woburn Biotech firm was awarded \$2.4 million Phase 2 SBIR grant over a two year period to develop a treatment for Alzheimer’s disease. The grant was from The National Institute on Aging (NIA). To treat Alzheimer’s, Aphios has developed APH-0703, a potent protein kinase C modulator. The company is working with Louisiana State University in Shreveport, La., to test APH-0703 with in vitro and in vivo efficacy, toxicity, and pharmacokinetic studies in mice with Alzheimer’s disease. “An even more impressive finding is that an oral formulation of APH-0703 rapidly reversed cognitive deficits in animal models of AD,” said J. Steven Alexander, LSU principal investigator, referring to APH-0703’s tests.</p>
	Mass High Tech, 1/24/12
26)	<p>Prosensa, a Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases, raised €23 million (US\$29.8 million) in new equity financing. The financing was led by new investor New Enterprise Associates (NEA) and was supported by existing investors, Abingworth, Life Sciences Partners, Gimv, Idinvest Partners, and MedSciences Capital.</p>
	PeHUB, 1/25/12
27)	<p>Tetraphase Pharmaceuticals Inc., a Watertown synthetic chemistry company could get \$40 million from a federal contract to develop an antibiotic to potentially treat illnesses resulting from biological threats such as anthrax, tularemia, or pestis. The money is part of a \$67.2 million, five-year contract awarded to Tetraphase and its partner CUBRC Inc. of Buffalo, N.Y., from the U.S. Department of Health and Human Services (HHS) Biomedical Advanced Research and Development Authority (BARDA). The contract is to develop Tetraphase’s lead compound, TP-434, to treat abdominal infections arising from biotreats.</p>
	Mass High Tech, 1/25/12